CELDARA MEDICAL, LLC

Address

16 CAVENDISH CT
LEBANON, NH, 03766-1441

http://celdaramedical.com

Information

DUNS: 828763263
# of Employees: 16

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Preclinical development of inhalable glutaredoxin-1 for the treatment of IPF

    Amount: $750,396.00

    DESCRIPTION provided by applicant Idiopathic pulmonary fibrosis IPF kills about persons in the United States each year There are currently around Americans afflicted with this fat ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  2. Development of GIFT4: a B cell focused immunotherapy for cancer

    Amount: $999,088.00

    Project Summary Our goal is to develop a novel immunotherapy for the treatment of melanoma and potentially a wide array of tumors Although surveillance by the immune system eliminates cancer cells i ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  3. IGF OT IGF MULTIPLEXED BIOMARKER ASSAY FOR CLASSIFICATION OF PATIENTS WITH SYSTEMIC SCLEROSIS

    Amount: $1,499,989.00

    Not Available

    SBIRPhase II2015Department of Health and Human Services
  4. Preclinical Development of BILT, a Next-Generation Immunotoxin Therapy for CTCL

    Amount: $299,052.00

    DESCRIPTION provided by applicant The long term aim of this project is to advance BILT for clinical approval which will provide clinicians with a powerful addition to the armamentarium for treatin ...

    SBIRPhase I2015Department of Health and Human Services
  5. Therapy of transplantation-induced oxidative injury using polymeric antioxidants

    Amount: $1,478,801.00

    DESCRIPTION provided by applicant Ischemia reperfusion I R injury during renal transplantation surgery is responsible for oxidative stresses which result in immune activation and graft rejection ...

    SBIRPhase II2015Department of Health and Human Services
  6. Preclinical development of inhalable glutaredoxin-1 for the treatment of IPF

    Amount: $224,944.00

    DESCRIPTION provided by applicant Idiopathic pulmonary fibrosis IPF kills about persons in the United States each year There are currently around Americans afflicted with this fat ...

    SBIRPhase I2015Department of Health and Human Services
  7. Destroying the HIV-1 provirus by utilizing components of the CRISPR/Cas system

    Amount: $451,598.00

    DESCRIPTION (provided by applicant): The goal of this project is to develop a plasmid-based therapy that will destroy the integrated HIV-1 DNA (HIV- 1 provirus) in infected cells. Current HIV-1 anti-r ...

    SBIRPhase I2014Department of Health and Human Services
  8. Dampening CAR therapy-induced cytokine storm with anti-GM-CSF antibodies

    Amount: $224,985.00

    DESCRIPTION (provided by applicant): The long-term aim of this project is to reduce or eliminate the serious adverse events associated with cellular immunotherapy used to treat cancer. The current imp ...

    SBIRPhase I2014Department of Health and Human Services
  9. Therapy of transplantation-induced oxidative injury using polymeric antioxidants

    Amount: $225,000.00

    DESCRIPTION (provided by applicant): Ischemia-reperfusion (I/R) injury during renal transplantation surgery is responsible for oxidative stresses which result in immune activation and graft rejection. ...

    SBIRPhase I2014Department of Health and Human Services
  10. PHASE I, SBIR CONTRACT, N43TR-14-001,?MUTIPLEXED BIOMARKER ASSAY FOR CLASSIFICATION OF PATIENTS?.

    Amount: $223,419.00

    Not Available

    SBIRPhase I2014Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government